Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

OptimizeRx (OPRX) Shares Outstanding (2016 - 2026)

OptimizeRx's Shares Outstanding history spans 16 years, with the latest figure at $20.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 1.52% to $20.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.5 million, a 1.52% increase, with the full-year FY2025 number at $20.5 million, up 1.52% from a year prior.
  • Shares Outstanding hit $20.5 million in Q4 2025 for OptimizeRx, up from $20.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding for OPRX hit a ceiling of $20.5 million in Q4 2025 and a floor of -$1.7 million in Q2 2023.
  • Historically, Shares Outstanding has averaged $13.2 million across 5 years, with a median of $18.1 million in 2021.
  • Biggest five-year swings in Shares Outstanding: surged 893612.53% in 2022 and later tumbled 109.57% in 2023.
  • Tracing OPRX's Shares Outstanding over 5 years: stood at $17.9 million in 2021, then grew by 2.39% to $18.3 million in 2022, then rose by 8.81% to $19.9 million in 2023, then increased by 1.48% to $20.2 million in 2024, then rose by 1.52% to $20.5 million in 2025.
  • Business Quant data shows Shares Outstanding for OPRX at $20.5 million in Q4 2025, $20.3 million in Q3 2025, and $20.3 million in Q2 2025.